These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 28178660

  • 1. PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
    Koncar RF, Chu Z, Romick-Rosendale LE, Wells SI, Chan TA, Qi X, Bahassi EM.
    Oncotarget; 2017 Feb 28; 8(9):15827-15837. PubMed ID: 28178660
    [Abstract] [Full Text] [Related]

  • 2. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
    Higuchi F, Fink AL, Kiyokawa J, Miller JJ, Koerner MVA, Cahill DP, Wakimoto H.
    Mol Cancer Ther; 2018 Dec 28; 17(12):2551-2563. PubMed ID: 30217967
    [Abstract] [Full Text] [Related]

  • 3. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L, Cai J, Tan Z, Meng X, Li R, Li Y, Jiang C.
    Cancer Res Treat; 2021 Apr 28; 53(2):367-377. PubMed ID: 33070553
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.
    Shen Y, Li J, Nitta M, Futalan D, Steed T, Treiber JM, Taich Z, Stevens D, Wykosky J, Chen HZ, Carter BS, Becher OJ, Kennedy R, Esashi F, Sarkaria JN, Furnari FB, Cavenee WK, Desai A, Chen CC.
    Oncotarget; 2015 May 20; 6(14):11751-67. PubMed ID: 26059434
    [Abstract] [Full Text] [Related]

  • 8. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity.
    Tateishi K, Higuchi F, Miller JJ, Koerner MVA, Lelic N, Shankar GM, Tanaka S, Fisher DE, Batchelor TT, Iafrate AJ, Wakimoto H, Chi AS, Cahill DP.
    Cancer Res; 2017 Aug 01; 77(15):4102-4115. PubMed ID: 28625978
    [Abstract] [Full Text] [Related]

  • 9. IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.
    Wang JB, Dong DF, Wang MD, Gao K.
    Asian Pac J Cancer Prev; 2014 Aug 01; 15(1):427-32. PubMed ID: 24528069
    [Abstract] [Full Text] [Related]

  • 10. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
    Shi J, Sun B, Shi W, Zuo H, Cui D, Ni L, Chen J.
    Tumour Biol; 2015 Feb 01; 36(2):655-62. PubMed ID: 25283382
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
    Momota H, Nerio E, Holland EC.
    Cancer Res; 2005 Aug 15; 65(16):7429-35. PubMed ID: 16103096
    [Abstract] [Full Text] [Related]

  • 16. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
    Zuco V, De Cesare M, Zaffaroni N, Lanzi C, Cassinelli G.
    Oncotarget; 2015 Apr 20; 6(11):8736-49. PubMed ID: 25826089
    [Abstract] [Full Text] [Related]

  • 17. PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule.
    Lund-Andersen C, Patzke S, Nähse-Kumpf V, Syljuåsen RG.
    Radiother Oncol; 2014 Feb 20; 110(2):355-61. PubMed ID: 24502970
    [Abstract] [Full Text] [Related]

  • 18. Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
    Xu Q, Ahmed AK, Zhu Y, Wang K, Lv S, Li Y, Jiang Y.
    Biochem Biophys Res Commun; 2018 May 23; 499(4):882-888. PubMed ID: 29625108
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.